Key Highlights
- Shares closed up 9.84% at $14.62, trading near their 52-week high of $15.30.
- The company raised 2026 Revenue guidance to $410 million to $420 million, up from $350 million to $370 million.
- Stronger U.S. Demand for its two approved cell therapy products drove the higher outlook.
- Baird lifted its price target to $11 from $6 while maintaining a Neutral rating.
- Investors are watching for a lifileucel non-small cell lung cancer program update expected in the fourth quarter.
Raised Guidance Extends the Stock's Recent Momentum
Iovance Biotherapeutics (NASDAQ:IOVA) shares closed sharply higher after the company raised its 2026 revenue guidance to a range of $410 million to $420 million, up from a prior range of $350 million to $370 million. Iovance Biotherapeutics is a commercial-stage biotechnology company that develops tumor-infiltrating lymphocyte cell therapies, with its flagship product having received accelerated FDA approval in 2024 as the first cell therapy approved for a solid tumor.
Management attributed the higher outlook to stronger-than-expected U.S. demand for its two approved cell therapy products, extending a rebound that had already been building after a profit-taking dip earlier in the week.
Baird Raises Price Target Following the Guidance Update
Baird lifted its price target on the stock to $11 from $6 while maintaining a Neutral rating, reflecting improved confidence in the company's near-term revenue trajectory following the updated guidance. Shares traded on above-average Volume as investors digested the news.
Analyst Targets Remain Mixed Despite the Rally
Analyst consensus on the stock remains Moderate Buy, though price targets vary widely, from around $12.90 to $20 at the high end, meaning many individual targets still sit below the current share price even after today's advance. That spread reflects differing views on how durable the company's recent demand strength will prove.
Lung Cancer Program Update Looms as Next Catalyst
Investors are watching for an update on the company's lifileucel program in non-small cell lung cancer, expected in the fourth quarter, as a potential next catalyst for the stock. The broader market was also firmer on the day, with easing oil and bond yields supporting risk appetite, while the healthcare sector ETF traded roughly flat.






Please wait processing your request...